Results of Akili’s EndeavorRx™ Clinical Study Published in Nature Digital Medicine, Demonstrate Improvements in Pediatric ADHD Impairments and Symptoms in Daily Life

"Data on the treatment’s effect on daily functioning support existing evidence showing improvements across objective measures of attention
Significant improvements in impairments and symptoms seen by parents in daily life, both when used alone and alongside stimulant medication
Improvements observed by parents and clinicians increased with longer duration of treatment and persisted one month following treatment.
Akili Interactive (“Akili” or “Company"), today announced the publication of full data from a multi-site open-label study (STARS Adjunct) evaluating the impact of EndeavorRxTM (AKL-T01) on symptoms and functional impairments in children with attention- deficit/hyperactivity disorder (ADHD). Statistically significant improvement was demonstrated in all predetermined endpoints of the study, which included parent and clinician ratings of children’s ADHD symptoms and related impairments in daily life. The results have been published in the international peer-reviewed journal, Nature Digital Medicine..." Lire la suite